PHIO earnings analysis
What we found in PHIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Phio Pharmaceuticals posted a net loss of $4.0 million in Q1 2026, significantly increasing from a $1.8 million loss in Q1 2025. With R&D expenses surging by 215% to $2.8 million due to intensified clinical activities for PH-762, the company continues to focus its resources on product development despite a dwindling cash position of $17 million, down from $21 million at the end of 2025.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Surge in R&D Expenses
- R&D expenses rose 215% to $2.8 million compared to $1.9 million in Q1 2025.
- Worsening Net Loss
- The net loss increased to $4.0 million from a $1.8 million loss a year earlier.
- Cash Position Declines
- Cash and cash equivalents decreased to $17 million from $21 million at December 31, 2025.
- Increased Operating Expenses
- Total operating expenses increased to $4.2 million from $1.8 million in Q1 2025.
- Effective Cost Management Focus
- Phio emphasizes a streamlined cost structure while driving clinical advancements.
- Clinical Advancements
- PH-762 is progressing, with a Phase 1b trial completed, showing promising anti-tumor responses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Escalating Clinical Trial Costs
- Clinical trial costs increased significantly, with R&D expenses up by $1.9 million due to intensified trials.
- Diminished Cash Runway
- The cash position fell to $17 million, raising concerns over operational sustainability.
- Higher Net Loss Trajectory
- Net loss trajectory has worsened year-over-year, raising doubts about financial health.
What they said about what is next.
No specific revenue or EPS guidance was provided in the MD&A.
The filing reads worse than the one before it.
What came before.
- 10-K · March 5, 2026
- Phio is a clinical-stage immuno-oncology company developing INTASYL® self-delivering siRNA therapeutics, with lead candidate PH-762 showing promising Phase 1b activity (65% pathologic response in cSCC) in a fully…
- 10-Q · November 13, 2025
- Phio reported a larger operating loss in Q3 2025 as R&D and G&A spending increased while clinical progress on PH-762 showed meaningful pathologic responses. Cash and liquidity improved materially after recent financings…
- 10-K · March 31, 2025
- Phio is a single‑segment clinical‑stage biotech commercializing its INTASYL® self‑delivering siRNA platform focused on immuno‑oncology. The company reported encouraging early Phase 1b intratumoral PH‑762 signals (2…
- 10-Q · May 9, 2024
- Phio reported lower operating expenses and a smaller net loss for the quarter ended March 31, 2024 as management continues to shift resources to clinical development (PH-762). Cash declined to $6.475 million at March…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PHIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever